Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis

Scott, 2010, Rheumatoid arthritis, Lancet, 376, 1094, 10.1016/S0140-6736(10)60826-4

Klein, 2005, Cannabinoid-based drugs as anti-inflammatory therapeutics, Nat Rev Immunol, 5, 400, 10.1038/nri1602

Matsuda, 1990, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346, 561, 10.1038/346561a0

Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365, 61, 10.1038/365061a0

Howlett, 2002, International Union of Pharmacology. XXVII. Classification of cannabinoid receptors, Pharmacol Rev, 54, 161, 10.1124/pr.54.2.161

Richardson, 2008, Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis, Arthritis Res Ther, 10, R43, 10.1186/ar2401

Bartok, 2010, Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis, Immunol Rev, 233, 233, 10.1111/j.0105-2896.2009.00859.x

Neumann, 2010, Rheumatoid arthritis progression mediated by activated synovial fibroblasts, Trends Mol Med, 16, 458, 10.1016/j.molmed.2010.07.004

Hanus, 1999, HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor, Proc Natl Acad Sci USA, 96, 14228, 10.1073/pnas.96.25.14228

Arnett, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, 315, 10.1002/art.1780310302

Altman, 1986, Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association, Arthritis Rheum, 29, 1039, 10.1002/art.1780290816

Zhang, 2013, IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis, Inflammation, 36, 103, 10.1007/s10753-012-9524-8

Ishiyama, 1996, A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet, Biol Pharm Bull, 19, 1518, 10.1248/bpb.19.1518

Miller, 2011, The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications, Pharmacol Rev, 63, 461, 10.1124/pr.110.003491

Mbvundula, 2006, Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro, J Pharm Pharmacol, 58, 351, 10.1211/jpp.58.3.0009

Ofek, 2006, Peripheral cannabinoid receptor, CB2, regulates bone mass, Proc Natl Acad Sci USA, 103, 696, 10.1073/pnas.0504187103

Maresz, 2007, Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells, Nat Med, 13, 492, 10.1038/nm1561

Karsak, 2007, Attenuation of allergic contact dermatitis through the endocannabinoid system, Science, 316, 1494, 10.1126/science.1142265

Merriam, 2008, Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats, Neurosci Lett, 445, 130, 10.1016/j.neulet.2008.08.076

Sophocleous, 2011, The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation, Endocrinology, 152, 2141, 10.1210/en.2010-0930

McInnes, 2010, State-of-the-art: rheumatoid arthritis, Ann Rheum Dis, 69, 1898, 10.1136/ard.2010.134684

Buch, 2011, New therapies in the management of rheumatoid arthritis, Curr Opin Rheumatol, 23, 245, 10.1097/BOR.0b013e3283454124

Selvi, 2008, Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes, Clin Exp Rheumatol, 26, 574

Ross, 1999, Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630, Br J Pharmacol, 126, 665, 10.1038/sj.bjp.0702351

Rinaldi-Carmona, 1998, SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor, J Pharmacol Exp Ther, 284, 644

Portier, 1999, SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist, J Pharmacol Exp Ther, 288, 582

Tolboom, 2002, Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10, Ann Rheum Dis, 61, 975, 10.1136/ard.61.11.975

Cohen, 2009, Targeting protein kinases for the development of anti-inflammatory drugs, Curr Opin Cell Biol, 21, 317, 10.1016/j.ceb.2009.01.015

Suzuki, 2000, The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts, FEBS Lett, 465, 23, 10.1016/S0014-5793(99)01717-2

Kirchmeyer, 2008, All-trans retinoic acid suppresses interleukin-6 expression in interleukin-1-stimulated synovial fibroblasts by inhibition of ERK1/2 pathway independently of RAR activation, Arthritis Res Ther, 10, R141, 10.1186/ar2569

Rajesh, 2008, CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration, Br J Pharmacol, 153, 347, 10.1038/sj.bjp.0707569

Gertsch, 2004, Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways, FEBS Lett, 577, 563, 10.1016/j.febslet.2004.10.064